Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation

Oral Oncology

Volumn 51, Issue 5, 2015, Pages 529-535

  Shah, Ketan ^a   Te Marvelde, Luc ^a   Collins, Marnie ^a   De Abreu Lourenco, Richard ^b   D'Costa, Ieta ^a   Coleman, Andrew ^a   Fua, Tsien ^a   Liu, Chen ^a   Rischin, Danny ^a   Lau, Eddie ^a   Corry, June ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Economics; Follow up studies; Head and neck neoplasms; Health services research; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EXAMINATION; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC IMAGING; DRUG SAFETY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOSPITAL COST; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OUTPATIENT; OVERALL SURVIVAL; PATIENT CODING; PATIENT SAFETY; PET-CT SCANNER; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; CARCINOMA, SQUAMOUS CELL; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK NEOPLASMS; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECURRENT DISEASE;

CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HOSPITAL COSTS; HUMANS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84933672154     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.02.005     Document Type: Article

References (26)

1. Fahy BN. Follow-up after curative resection of colorectal cancer. Ann Surg Oncol 2014;21:738-46.
2. Improving outcomes in head and neck cancers - the manual. National Institute for Health and Care Excellence, United Kingdom; 2004.
3. SIGN 90: Diagnosis and management of head and neck cancer. Scottish Intercollegiate Guidelines Network; 2006.
4. NCCN Clinical practice guidelines in oncology - head and neck cancers version 2; 2013.
5. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment fdg pet or fdg pet/ct imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083-95.
6. Corry J, Peters L, Fisher R, et al. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 2008;30:737-42.
7. Bar-Ad V, Mishra M, Ohri N, Intenzo C. Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma. Rev Recent Clin Trials 2012;7:36-41.
8. Corry J, Rischin D, Hicks RJ, Peters LJ. The role of pet-ct in the management of patients with advanced cancer of the head and neck. Curr Oncol Rep 2008;10:149-55.
9. Porceddu SV, Adams G, Gundelach R, Pryor DI. Does fluorodeoxyglucose pet add to the management of the neck following curative radiotherapy in head and neck cancer compared with computed tomography? Expert Rev Anticancer Ther 2013;13:279-84.
10. Flynn CJ, Khaouam N, Gardner S, et al. The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2010;22:868-73.
11. Kothari P, Trinidade A, Hewitt RJ, Singh A, O'Flynn P. The follow-up of patients with head and neck cancer: An analysis of 1, 039 patients. Eur Arch Otorhinolaryngol 2011;268:1191-200.
12. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9.
13. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-50S.
14. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007;29(11):986-95.
15. Castaldi P, Rufini V, Bussu F, et al. Can "early" and "late" 18F-FDG PET/CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 2012;103:63-8.
16. Prestwich RJ, Subesinghe M, Gilbert A, Chowdhury FU, Sen M, Scarsbrook AF. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma. Clin Radiol 2012;67:966-75.
17. Lyman GH. Counting the costs of cancer care. Lancet Oncol 2013;14:1142-3.
18. Health expenditure Australia 2010-11. Australian Institute for Health and Welfare; 2013.
19. Manikantan K, Khode S, Dwivedi RC, et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev 2009;35:744-53.
20. Lester SE, Wight RG. 'When will I see you again?' Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients. Clin Otolaryngol 2009;34:546-51.
21. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009;115:4586-94.
22. Paidpally V, Tahari AK, Lam S, et al. Addition of 18F-FGD PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med 2013;54:2039-45.
23. Jung YH, Song CM, Park JH, et al. The efficacy of current regular follow-up policy after treatment for head and neck cancer: the need for individualized and obligatory follow-up strategy. Head Neck; 2013: n/a-n/a.
24. Smith KA, Rudmik L. Cost collection and analysis for health economic evaluation. Otolaryngol Head Neck Surg 2013;149:192-9.
25. Mehnert A, Koch U, Sundermann C, Dinkel A. Predictors of fear of recurrence in patients one year after cancer rehabilitation: a prospective study. Acta Oncol 2013;52:1102-9.
26. Giese-Davis J, Waller A, Carlson L, et al. Screening for distress, the 6th vital sign: Common problems in cancer outpatients over one year in usual care: associations with marital status, sex, and age. BMC Cancer 2012;12:441.